Table 1:
Characteristics of atrial fibrillation patients by sleep apnea status, MarketScan 2007–2014
| Sleep apnea (ICD)a | No sleep apnea | |
|---|---|---|
| N | 59,969 | 323,246 |
| Age, mean (SD) | 62.8 ± 11.7 | 63.3 ± 11.8 |
| CHA2DS2-VASc score, mean (SD) | 1.5 ± 1.2 | 1.5 ± 1.3 |
| Mean inpatient visits, mean (SD) | 0.3 ± 0.8 | 0.2 ± 0.7 |
| Mean outpatient visits, mean (SD) | 49.6 ± 89.5 | 41.9 ± 83.4 |
| Age, y | ||
| >65, N (%) | 13,100 (22) | 73,109 (23) |
| >75, N (%) | 10,427 (17) | 60,766 (19) |
| Female, N (%) | 17,335 (29) | 97,023 (30) |
| Diabetes, N (%) | 9,872 (17) | 45,006 (14) |
| Hypertension, N (%) | 24,135 (40) | 127,120 (39) |
| Comorbidities | ||
| Depression, N (%) | 3,208 (5) | 15,656 (5) |
| Alcohol abuse, N (%) | 76 (0) | 1,022 (0) |
| Medications | ||
| Hypnotics, N (%) | 3,759 (6) | 17,692 (6) |
| Anti-depressants, N (%) | 8,350 (14) | 37,429 (12) |
| Varenicline, N (%) | 211 (0) | 1,307 (0) |
| Weight loss medication, N (%) | 373 (1) | 1,103 (0) |
| Thyroid medication, N (%) | 4,799 (8) | 26,013 (8) |
a
Primary exposure definition